Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nomacopan - Akari Therapeutics

Drug Profile

Nomacopan - Akari Therapeutics

Alternative Names: Coversin; EV 576; PAS-coversin; PAS-nomacopan; rEV 576; rVA576

Latest Information Update: 08 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evolutec
  • Developer Akari Therapeutics; Evolutec
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Antithrombotics; Antivirals; Eye disorder therapies; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathy; Guillain-Barre syndrome; Bullous pemphigoid
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathy
  • Phase II Bullous pemphigoid
  • Phase I/II Keratoconjunctivitis; Pneumonia
  • Preclinical Rheumatoid arthritis; Uveitis
  • No development reported Guillain-Barre syndrome; Myasthenia gravis; Sjogren's syndrome
  • Discontinued Asthma; Autoimmune disorders; Inflammation

Most Recent Events

  • 08 Oct 2020 Akari Therapeutics received US FDA clearance to proceed with investigator-led multi-center clinical trial in Pneumonia (associated with COVID-19 infections)
  • 06 Oct 2020 Pharmacodynamic, pharmacokinetic and adverse events data from a proof of principle clinical trial in pneumonia (associated with COVID-19 infections) released by Akari Therapeutics
  • 11 Sep 2020 Phase-III clinical trials in Thrombotic microangiopathy (In adolescents, In children, In infants, In neonates) in United Kingdom, Poland (SC, Injection) (EudraCT2020-000086-17)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top